SCHEMBL16640385

SCHEMBL16640385

Cc1cnc(-c2cnccn2)s1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.56
RECQL P46063 1/20 0.56
CDC7 O00311 1/20 0.47
DBF4 Q9UBU7 1/20 0.47
HRH3 Q9Y5N1 5/20 0.46
SRC P12931 1/20 0.44
CDK2 P24941 1/20 0.44
ZAP70 P43403 1/20 0.44
SYK P43405 1/20 0.44
CYP1A2 P05177 2/20 0.43
ALDH1A1 P00352 2/20 0.43
KDM4E B2RXH2 1/20 0.43
TRPM8 Q7Z2W7 1/20 0.39
NOS1 P29475 1/20 0.39
HSD17B10 Q99714 3/20 0.38
DCTPP1 Q9H773 2/20 0.38
POLB P06746 1/20 0.37
HPGD P15428 1/20 0.37
NR4A1 P22736 1/20 0.37
ESR2 Q92731 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8264429 0.77 HTT (0.66) HTTRECQLCDC7DBF4HRH3
SCHEMBL7864083 0.76 HTT (0.44) HTTRECQLCDC7DBF4HRH3
SCHEMBL13801156 0.75 HTT (0.59) HTTRECQLCDC7DBF4HRH3
SCHEMBL10002194 0.75 NOS1 (0.55) SRCCDK2ZAP70SYKNOS1
SCHEMBL12116515 0.74 ALDH1A1 (0.58) SRCCDK2ZAP70SYKCYP1A2
SCHEMBL30606304 0.74 ALDH1A1 (0.58) SRCCDK2ZAP70SYKCYP1A2
SCHEMBL19336777 0.74 KDM4E (0.53) HTTRECQLCDC7DBF4HRH3
SCHEMBL17790299 0.74 HTT (0.54) HTTRECQLCDC7DBF4HRH3
SCHEMBL1458916 0.74 HTT (0.62) HTTRECQLCDC7DBF4HRH3
SCHEMBL13416007 0.73 HTT (0.45) HTTRECQLCDC7DBF4HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3057963-B1 PIPERAZINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT BOEHRINGER INGELHEIM INT (DE) 2019-06-19 EP disclosed
US-9233953-B2 Derivatives of 4-(piperazinylcarbonyl)thiane-1, 1-dione which inhibit GlyT1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2016-01-12 US disclosed
US-9233953-B2 Derivatives of 4-(piperazinylcarbonyl)thiane-1, 1-dione which inhibit GlyT1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2016-01-12 US disclosed
US-20150105397-A1 Piperazine derivatives and the use thereof as medicament BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-04-16 US disclosed
US-20150105397-A1 Piperazine derivatives and the use thereof as medicament BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150105397-A1 Piperazine derivatives and the use thereof as medicament SLC6A7, SLC7A11, SLC7A1 HTT 762/4885RECQL 3355/4885CDC7 4807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.